Bioequivalence of a Liquid Formulation of Alpha 1 -Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha 1 -PI) in Alpha 1 -Antitrypsin Deficiency.

MLA

Barker, Alan F., et al. “Bioequivalence of a Liquid Formulation of Alpha 1 -Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha 1 -PI) in Alpha 1 -Antitrypsin Deficiency.” COPD, vol. 14, no. 6, Dec. 2017, pp. 590–96. EBSCOhost, https://doi.org/10.1080/15412555.2017.1376044.

APA

Barker, A. F., Campos, M. A., Brantly, M. L., Stocks, J. M., Sandhaus, R. A., Lee, D., Steinmann, K., Lin, J., & Sorrells, S. (2017). Bioequivalence of a Liquid Formulation of Alpha 1 -Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha 1 -PI) in Alpha 1 -Antitrypsin Deficiency. COPD, 14(6), 590–596. https://doi.org/10.1080/15412555.2017.1376044

Chicago

Barker, Alan F, Michael A Campos, Mark L Brantly, James M Stocks, Robert A Sandhaus, Douglas Lee, Kimberly Steinmann, Jiang Lin, and Susan Sorrells. 2017. “Bioequivalence of a Liquid Formulation of Alpha 1 -Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha 1 -PI) in Alpha 1 -Antitrypsin Deficiency.” COPD 14 (6): 590–96. doi:10.1080/15412555.2017.1376044.